Articles related to TARGETED THERAPIES

In a recent phase 3 trial, alectinib has shown a notable improvement in both disease-free and CNS disease-free survival in patients with ALK-positive NSCLC, indicating a robust alternative to platinum-based chemotherapy regimens.

Mirvetuximab soravtansine represents a pivotal shift in treating platinum-resistant ovarian cancer, demonstrating not only improved survival outcomes but also a higher response rate compared to standard chemotherapy.

In a recent phase 3 trial, the addition of brentuximab vedotin to standard chemotherapy not only achieved a notable improvement in 3-year event-free survival rates for pediatric Hodgkin’s lymphoma patients but also maintained a comparable safety profile, underscoring the therapeutic potential of targeted treatments in this population.

The AHS’s new consensus underscores the pivotal role of CGRP-targeting therapies in migraine prevention, marking a key advancement in patient care. These treatments offer a focused approach, approved for both episodic and chronic migraine, setting a new standard in therapeutic strategies.

Explore the latest findings on vibecotamab’s potential in R/R AML treatment, revealing promising results with an optimized dosing regimen that mitigates cytokine response syndrome while improving patient outcomes.

Explore groundbreaking trials from SABCS 2023, revealing the potential of sacituzumab govitecan and datopotamab deruxtecan in enhancing treatment paradigms for metastatic breast cancer, spotlighting pivotal advancements in antibody-drug conjugate therapy.